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Abstract
Purpose The major histocompatibility complex class I
related A (MICA) and MICB molecules are ligands of
NKG2D receptors on natural killer cells, gamma/delta T
cells, and CD8aß Tcells that mediate host antitumor immune
response. The role of MICA-TM and MICB C1_2_A alleles
in patients with colorectal cancer has not yet been
investigated.
Methods We have analyzed the MICA-TM and MICB
C1_2_A polymorphisms in colorectal cancer patients (n=
79) by polymerase chain reaction amplification, subse-
quent electrophoresis, and sequencing in comparison to a
previously analyzed cohort of healthy controls (n=306).
Allele frequencies obtained for MICA-TM and MICB
C1_2_A were compared to histopathological data regard-
ing tumor invasion, disease progression, microsatellite in-
stability, and the presence of KRAS mutations (codon 12)
and analyzed for possible impact on tumor-related survival
(n=61).
Results Allele frequencies of MICA-TM and MICB
C1_2_A polymorphisms were not different in patients with
colorectal cancer in comparison to normal controls. In
colorectal cancer patients, MICA-TM A4 allele was directly
and MICA-TM A5 allele was inversely associated with
lymph node involvement and advanced UICC stages.
Tumor-related survival in colorectal cancer patients was
significantly reduced in the presence of the MICA-TM A4
allele (p=0.015). In patients with microsatellite stable
tumors, survival was reduced in association with the
MICA-TM A4 allele (p=0.006) and MICA-TM A9 allele
(p=0.034), but increased in patients showing the MICA-TM
A5 allele (p=0.042).
Conclusions Specific MICA-TM alleles seem to influence
tumor progression and midterm survival of patients with
colorectal cancer, indicating an important role of host innate
immune predisposition involving NKG2D mediated anti-
tumor response.
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The major histocompatibility complex class I chain related
A (MICA) and MICB molecules are ligands of NKG2D
receptors on natural killer (NK) cells, gamma/delta T cells,
NKT cells, and CD8aß T cells, and mediate antitumor
immune responses by stimulating innate and adaptive
immune surveillance [1–3]. Several polymorphisms have
been reported for MICA and MICB coding and noncoding
sequences, located within the MHC class I region close to
the tumor necrosis factor gene [4, 5]. The MICA-TM
microsatellite polymorphism is present in exon 5 with eight
alleles (A4, A5, A5.1, A6, A7, A8, A9, and A10), while the
MICB gene contains a microsatellite polymorphism named
C1_2_A in intron 1 comprising 16 alleles [6, 7]. Different
MICA molecules were reported to vary in their affinities to
soluble NKG2D receptors, which may influence antitumor
immune responses [5, 8]. Recent studies have shown
increased serum levels of soluble MICA molecules in
patients with various malignancies with a correlation to
advanced tumor stages [9]. Circulating tumor-derived
soluble MICA molecules induce downregulation of
NKG2D receptors on natural killer cells and thereby
decrease responsiveness of tumor-antigen-specific effector
T cells [10]. The mechanism of T and NK cell silencing by
down regulation of NKGD cells induced by soluble ligands
or chronic exposure to cell surface bound ligands may
represent an important mechanism for tumor cells to escape
host antitumor immune responses. Some reports have
indicated associations of specific MICA alleles with
epithelial tumors of the nasopharynx and gastric mucosa,
with hematopoetic neoplasia and with chronic inflammato-
ry and autoimmune disorders [11–15]. The allele and
genotype frequencies of MICA-TM and MICB C1_2_A
microsatellite polymorphisms in patients with colorectal
cancer and a possible immunogenetic predisposition for the
development of colorectal cancer or tumor progression have
not yet been investigated. We have therefore analyzed the
MICA-TM and MICB C1_2_A polymorphisms in samples
of normal colon mucosa and tumor tissue from colorectal
cancer patients in comparison to a cohort of healthy
controls and investigated possible correlations to tumor
characteristics and disease progression.
Methods
Patients and Controls
Seventy-nine patients with colorectal cancer were analyzed.
The patients had been treated between Jan. 1998 and
Dec. 2002 according to the principles of oncologic surgery,
and tumors were classified according to TNM/UICC
criteria following histopathological examination. Mean
age was 67.4±10.9 years (range, 34–88 years), 52.5% of
the patients were male and 47.5% female. Sixty-eight
patients had sporadic colorectal cancer. Patients with
evidence for polyposis cancer syndromes were excluded
from the study. Eleven patients with clinical evidence for
hereditary nonpolyposis colon cancer according to
Bethesda criteria were analyzed separately for microsatellite
instability to investigate a possible correlation of the DNA
replication error pathway with alterations in host antitumor
immunity [16]. Primary tumors were localized in the colon
(n=54) and rectum (n=25). Twenty-three patients had
UICC stage IV tumors with distant metastasis localized in
the liver (n=12), lungs (n=6), peritoneum (n=4), or at
multiple sites (n=4). Results of lymph node involvement
(N-classification) were included in the study, when at least
12 lymph nodes were removed and histopathologically
examined. Frequencies of MICA-TM and MICB C1_2_A
polymorphisms in colorectal cancer patients were compared
to a previously analyzed cohort of healthy controls (n=306)
[17]. The study was approved by the local ethics commit-
tee, and patients' informed consent was obtained.
Postoperative follow-up was performed according to the
recommendations of the Munich cancer center and pro-
spectively documented in an institutional data base. Follow-
up intervals were initially every 6 months for 2 years, then
yearly for up to the sixth year and at 2-year intervals for up
to 10 years, including clinical examination, determination
of carcinoembryonic antigen levels, upper abdomen sonog-
raphy, abdominal CT scan, and total colonoscopy. Recto-
scopy was performed in patients with rectal cancer or with
an anastomosis below 12 cm as measured from the
anocutanous line. Only patients with complete histopatho-
logical examination according to the TNM/UICC criteria
and prospective follow-up were considered for analysis of
survival times. Mean follow-up ±SD was 56.2±36.3 months
(range, 1–106 months).
MICA-TM and MICB C1_2_A Genotyping
MICA-TM and MICB C1_2_A polymorphisms were geno-
typed in genomic DNA isolated from normal colonic mucosa
and colorectal tumor tissue, respectively [18]. Allele fre-
quencies of MICA-TM and MICB C1_2_A polymorphisms
were compared to a group of 306 healthy control persons,
analyzed previously (mean age, 62.8±11.8 years; sampling
period Jan. 1997 to Dec. 2000) [17]. The MICA-TM
polymorphism was analyzed by polymerase chain reaction
(PCR) amplification with the primers 5′-CAGAGTCAT
TGGCAGACA-3′ (5′-Fam-labeled) and 5′-TTCTTCTTA
CAACAACGGAC-3′. The PCR products were separated
by electrophoresis on denaturating 6% 0.3-mm polyacryl-
amide gels in the ALFexpress sequencer (Amersham
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MICA-TM alleles was controlled in 20 HLA-A, B, DR-
typed families. Sequencing confirmed the allele size deter-
mined. As internal standards, a 73-bp PCR product from the
transforming growth factor receptor II and ALFexpress Sizer
150 for MICB C1_2_A were used, respectively.
MICB C1_2_A alleles of interest, including the gold
standards, were sequenced either directly as PCR products or
after subcloning into the vector pCR2.1 (Invitrogen). For
sequence analysis of MICB C1_2_A microsatellite, alleles
were amplified with the primers 5′-CCATAGTGTTTTCC
ATTGCAGGC-3′ and 5′-AGCCATGAGAAGCTAT
GTGGGG-3′. The PCR products were purified using a QIA
Quick PCR Purification Kit (Qiagen, Hilden, Germany) and
weresequencedusingtheABIPRISM
TM dye terminator cycle
sequencing kit on an ABI 373 DNA sequencer. The raw data
were analyzed by the ABI Sequence Analysis program.
Screening for Tumor Microsatellite Instability and KRAS
Oncogene Mutations
Analysis of tumor microsatellite instability (MIN) was
performed using the microsatellite markers BAT26,
BAT40, TGFBR2(A)10, BAX(G)8, and the dinucleotide
repeat MFD15 (D17S250), with modifications according
to the meeting report of the National Cancer Institute
Workshop on microsatellite instability [16]. Tumors exhib-
iting instability at 0–1 loci analyzed were considered as
presenting low MIN and at ≥2 loci as high microsatellite
instability (MIN-h).
Tumor DNA was screened for KRAS mutations in codon
12 (glycine, GGT) by primer-mediated restriction fragment
length polymorphism (RFLP) analysis. The primers used
were ACTGAATATAAACTTGTGGTAGTTGGACCT and
TCATGAAAATGGTCAGAGAA, the underlined base with-
in the forward primer introduces a BstN I restriction site in
the amplified wild-type sequence. The colon carcinoma cell
line SW480 carrying a homozygous Val mutation at codon
12 was used as a positive control for RFLP analysis.
Additionally, all tumor DNA samples displaying mutated
KRAS sequences at codon 12 in RFLP analysis were further
analyzed by sequencing in order to confirm to results of
RFLP analysis and to determine which mutation was present.
For sequence analysis, a 288-bp amplificate was generated
using the primers ACTGGTGGAGTATTTGATAG and
ACTCATGAAAATGGTCAGAG.
Statistical Analysis
Haplotype gene frequencies were determined by gene
counting assuming homozygosity, if at a given locus only
one allele could be identified. Correlations to histopatholog-
ical parameters were performed comparing MICA-TM and
MICB C1_2_A alleles with tumor invasion, lymph node
involvement, presence of distant metastasis, and UICC
stages. Statistical significance for the two-point associations
was tested by Chi-square calculation in the 2×2 table and
Pearson′s coefficient, Fisher's exact test (two-sided) or phi
coefficient was used, when appropriate. Survival times were
calculated by Kaplan–Meier curves, and the log rank test
was used for statistical analysis and comparison of different
variables. For multivariate analysis, Cox regression analysis
was performed using the Wald test for comparison of
variables. A p value of less than 0.05 was used to indicate
statistical significance. Statistical analysis was performed
using the SPSS statistical software (SPSS version 11.5).
Results
MICA-TM and MICB C1_2_A Allele Frequencies
Allele frequencies of MICA-TM and MICB C1_2_A in
colorectal cancer patients did not differ compared to a
cohort of healthy control individuals (Table I). Homozy-
gosity was most frequently observed in colorectal cancer
Table I Allele Frequencies (in %) of Microsatellites MICA-TM and
MICB C1_2_A in Colorectal Cancer Patients and Control Persons
Colorectal cancer patients (n=79) Controls (n=306)
MICA-TM allele
A4 11.9 11.7
A5 10.6 13.6
A5.1 43.1 37.0
A6 21.9 22.4
A9 12.5 15.3
MICB C1_2_A allele
CA14 16.6 18.5
CA15 19.2 10.5
CA16 n.d. 0.2
CA17 11.4 20.3
CA18 8.3 7.2
CA19 3.1. 1.1
CA20 3.7 4.1
CA21 8.0 8.9
CA22 4.3 7.2
CA23 5.6 5.9
CA24 14.8 10.9
CA25 4.8 3.9
CA26 n.d. 0.8
CA27 n.d. 0.5
Allele frequencies of control persons were reported in [18]
n.d. not detected in our patients' cohort
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patients) and for the MICB C1_2_A CA15 allele (n=4;
5.1% of all patients). Nonsignificant trends were observed
in our cohort regarding an increased MICB C1_2_A CA15
allele frequency (19.2% vs 10.5%) and a reduced CA17
allele frequency (11.4% vs 20.3%) in comparison to the
control group.
Association of MICA-TM and MICB C1_2_A Alleles
with Tumor-Associated Variables
MICA-TM and MICB C1_2_A alleles were investigated
for possible correlation to various tumor-associated varia-
bles, including tumor invasion, lymph node involvement,
presence of distant metastasis, UICC stages, microsatellite
instability, and detection of KRAS mutations (codon 12). As
shown in Table II, the MICA-TM A4 allele was associated
with the presence of distant metastasis (p=0.023). The
presence of the MICA-TM A5 allele showed an inverse
association to lymph node involvement (p=0.015), pres-
ence of distant metastasis (p=0.048), and advanced UICC
stages (p=0.003). The analysis of MICB C1_2_A alleles
showed an association of the CA14 allele with the presence
of distant metastasis (p=0.045) and of the CA21 allele with
advanced UICC stages (p=0.047).
Table II Comparison of MICA-TM Allele Frequencies with Tumor-
Associated Clinicopathological Parameters
Tumor classification MICA-TM allele
A4 A5 A5.1 A6 A9
Tumor invasion
T1/2 3/17 3/17 12/17 7/17 3/17
T3/4 11/44 8/44 32/44 18/44 11/44
Lymph node involvement
N0 9/51 11/51 39/51 20/51 11/51
N1-3 5/10 0/10
a 6/10 5/10 3/10
Distant metastasis
M0 8/47 12/47 35/47 17/47 11/47
M1 10/23
b 1/23
c 14/23 11/23 3/23
UICC stages
UICC I/II 4/30 10/30 22/30 11/30 5/30
UICC III/IV 14/39 2/39
d 26/39 17/39 9/39
ap<0.05
bp<0.023
cp<0.048
dp<0.02
MICA-TM/MICB C1_2_A Tumor-related parameters
Allele frequencies MIN (n=17) MIN-h (n=10) KRAS mutations (n=17)
MICA-TM allele
A4 6/21 4/21 4/21
A5 3/14 3/14 3/14
A5.1 10/56 7/56 9/56
A6 6/32 3/32 9/32
A9 4/16 2/16 5/16
MICB C1_2_A allele
CA14 7/24 3/24 3/24
CA15 4/28 3/28 4/28
CA16 n.d. n.d. n.d.
CA17 2/17 1/17 3/17
CA18 2/11 1/11 3/11
CA19 1/5 1/5 1/5
CA20 1/6 0/6 1/6
CA21 5/13 4/13* 4/13
CA22 2/7 1/7 3/7
CA23 1/9 0/9 4/9
CA24 4/24 4/24 4/24
CA25 1/6 0/6 3/6
CA26 n.d. n.d. n.d.
CA27 n.d. n.d. n.d.
Table III MICA-TM and
MICB C1_2_A Polymorphisms
in Colorectal Cancer Patients
with Regard to Tumor Micro-
satellite Stability or KRAS
Codon 12 Mutations
Microsatellite instability (MIN)
was defined as altered lengths of
PCR products typing five de-
fined mono- and dinucleotide
repeat markers. Tumor MIN was
considered when at least one
repeat locus showed altered
length and high microsatellite
instability (MIN-h) when two or
more microsatellite markers
showed tumor DNA replication
errors. For analysis, only MICA-
TM and MICB C1_2_A allele
frequencies >5% were consid-
ered
*p=0.047
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Microsatellite Instability, and KRAS Mutations
A trend for an increased frequency of the MICB C1_2_A
CA21 allele was observed in patients with colorectal tumors
showing high microsatellite instability as defined by different
lengths of PCR products in more than two markers (p=
0.047; Table III). Mutations in the KRAS oncogene were
detected in 17 colorectal cancer samples (20.9%). The KRAS
codon 12 mutation in tumor DNA samples were determined
by sequencing the PCR-generated fragment, and the follow-
ing mutations (12C: n=3;12D: n=4;12V:n=7;12S:n=
2) were detected. No correlation of MICA-TM alleles with
the presence of KRAS mutations was seen in the investigated
colorectal cancer patients. For MICB C1_2_A alleles, only a
trend toward an association with KRAS mutations was
observed for the CA 23 allele (p=0.087).
Analysis of Survival Times
Overall survival was analyzed in 61 patients with sporadic
colorectal carcinomas, followed and documented prospec-
tively in an institutional data base. Tumor-related postop-
erative survival was 86.0±4.4 months for patients
following complete tumor resection (R0-status; n=45) and
29.8±8.4 months for patients with tumor infiltrated resec-
tion margins or remaining distant metastasis (n=25;
p<0.001). Survival in the study cohort was related to
classical parameters of tumor progression like lymph node
involvement (p=0.005) and UICC stages (p=0.001)
according to univariate analysis, as shown in Table IV.
Further analysis indicated significantly shorter survival
times in patients positive for the MICA-TM A4 allele
(negative vs positive, 80.6 vs 51.9 months; p=0.015,
Fig. 1). Estimated 5-year survival times were 75% and
Tumor-related parameters Survival times
(mean ± SD; months)
(95% Confidence
interval)
p value
Tumor invasion
T1/2 (n=13) 85.0±9.6 (66.2–103.9) 0.113
T3/4 (n=48) 69.0±6.0 (57.1–80.8)
Lymph node involvement
N0 (n=34) 88.8±5.4 (78.1–99.4) 0.005
N1 (n=18) 65.3±8.9 (47.7–82.8)
N2 (n=9) 25.9±5.2 (6.9–44.9)
UICC stages
UICC I/II (n=30) 93.9±4.8 (84.4–103.4)
UICC III/IV (n=31) 52.7±7.3 (38.3–67.0) <0.001
A4
No (n=47) 80.6±5.6 (69.7–91.6)
Yes (n=14) 51.9±10.9 (30.5–73.2) 0.015
A5
No (n=47) 56.0±6.1 (56.0–80.2)
Yes (n=14) 87.4±6.3 (75.0–99.7) 0.074
A5.1
No (n=19) 65.2±9.8 (45.9–84.5)
Yes (n=42) 75.2±5.7 (63.9–86.6) 0.257
A9
No (n=48) 75.9±5.5 (65.0–86.8)
Yes (n=13) 59.5±10.6 (38.7–80.3) 0.106
CA24
No (n=42) 66.7±6.1 (54.7–78.7)
Yes (n=19) 84.3±8.6 (67.4–101.3) 0.108
Microsatellite instability (≥1 marker)
No (n=54) 71.7±5.7 (60.4–83.0)
Yes (n=7) 82.2±9.5 (63.6–100.9) 0.410
KRAS codon 12 mutations
No (n=44) 78.7±6.0 (66.9–90.4)
Yes (n=17) 58.7±9.5 (40.0–77.5) 0.093
Table IV Survival of Colorec-
tal Cancer Patients
Univariate analysis of tumor-
related survival times of patients
with indicated clinicopathologi-
cal parameters and selected
MICA-TM (A4, A5, A5.1, A9)
and MICB C1_2_A (CA24)
alleles in patients with colorectal
cancer (n=61). Kaplan–Meier
analysis and the log rank test
were used for comparisons and
statistical evaluation
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respectively. Multivariate analysis using the Cox regression
model after exclusion of the variable metastatic disease
indicated that presence of MICA-TM A4 allele (HR, 2.71;
95% CI, 1.13–6.49; p=0.025) and the tumor-related nodal
status (HR, 3.99; 95% CI, 1.61–9.86; p=0.003) were
independent prognostic variables.
Survival Analysis in Microsatellite Stable Tumors
We have further analyzed survival times in patients with
microsatellite stable tumors (n=54). As shown in Fig. 2,
prognostic relevance of MICA-TM A4 was even more
evident in microsatellite stable tumors (p=0.006) in
comparison to the other known prognostic variables such
as lymph node involvement (p=0.001) and UICC classifi-
cation (p<0.001, Table IV). In addition, MICA-TM A9 was
associated with reduced survival times (p=0.034) in micro-
satellite stable colorectal cancer patients, while the MICA-
TM A5 was inversely associated with a better prognosis
(p=0.042), providing evidence for a tumor suppressive
effect of the MICA-TM A5 allele (Table V). Further
combined analysis of colorectal cancer patients with
MICA-TM alleles positive for either A4 or A9 vs patients
negative for both A4 and A9 alleles had markedly reduced
survival times, as shown in Fig. 3 (p<0.001), with an
estimated 5-year survival of 36% vs 85%, respectively.
Multivariate analysis by Cox regression with inclusion of
the variables MICA-TM A4, A5, A9, lymph node involve-
ment, UICC stages, metastatic disease, and MICA-TM A4
or A9 positive indicated that metastatic disease (HR, 4.43;
95% CI, 1.66–11.81; p=0.003), lymph node involvement
(HR, 3.27; 95% CI, 1.14–9.30; p=0.026) and MICA-TM
A4 or A9 positive (HR, 4.02; 95% CI, 1.29–12.56;
p=0.016) were of independent prognostic relevance in
patients with microsatellite stable colorectal tumors.
Conclusions
The NK group 2, member D -NKG2D protein, is an
activating cell surface receptor expressed on NK cells and
on some T-cell subsets [19, 20]. Ligands of human NKG2D
include MICA, MICB, UL-16-binding proteins, and Letal
and are expressed on several tumors, especially on
epithelium-derived cancer cells [4]. Ligand binding of MICA
and MICB to the NKG2D receptor mediates innate antitumor
response by stimulation of NK cells and gamma delta T cells
and may modulate CD8aß T-cell responses [21, 22]. It was
shown that tumor cells expressing high levels of MICA and
NKG2D ligands were rejected by NK cells and CD8 alpha/
beta T cells and stimulated antitumor activity in a mouse
model [23, 24]. Analysis of the structure of the NKG2D-
120.00 100.00 80.00 60.00 40.00 20.00 0.00
1.0
0.8
0.6
0.4
0.2
0.0
cumulative survival 
months 
MICA-TM A4 negative 
MICA-TM A4 positive
Fig. 1 Survival analysis in relation to MICA-TM A4 allele haplotype.
Kaplan–Meier analysis of tumor-related survival times in association
with MICA-TM A4 allele in patients with colorectal cancer. Short
vertical lines indicate censored observations for comparison of patients
without (n=46) and with MICA-TM A4 allele (n=15, p=0.015)
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Fig. 2 MICA-TM A4 allele detection in microsatellite stable
colorectal cancer patients. Kaplan–Meier analysis of tumor-related
survival times in association with MICA-TM A4 allele in patients with
microsatellite stable colorectal cancer. Vertical lines indicate censored
observations for comparison of patients without (n=42) and with
MICA-TM A4 allele (n=12, p=0.006). The estimated 5-year survival
rate was 72% vs 38%, respectively
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crystallography showed the interaction of a NKG2D homo-
dimer with a single MICA monomer either at the alpha 1 or
alpha 2 domain forming a relatively stable Interaction, more
stable than other T-cell receptor–ligand or other NK cell
surface receptor–ligand complexes [25]. Groh et al. have
shown an increased tumor antigen cross-presentation and
priming of antitumor CD8 and CD4 T-cell responses by
loading of dendritic cells with MICA antibodies following
coculture with various tumor cells [21]. Recent studies
investigating mRNA expression on various benign and
malignant tissues and samples from patients with autoim-
mune diseases have shown a more widely distribution of
MICA and MICB expression independent of malignancies or
inflammation with the only exception for the central nervous
system [26]. So far, it remains unclear whether a different
genomic composition of MICA alleles might alter the ligand
affinity of MICA alleles to NKG2D receptors and thereby
modulate the host antitumor response.
In our study, we observed a significant association of
MICA-TM A4 allele with advanced tumor progression and
reduced tumor-related survival times. In contrast, patients
with the MICA-TM A5 allele had a remarkably low rate of
tumor lymph node invasion and less distant metastases.
Furthermore, in microsatellite stable tumors, genomic
MICA-TM A4 and A9 alleles were related to advanced
tumor progression and shorter tumor-related survival, while
the MICA-TM A5 allele was again found to have a tumor
suppressive effect. These findings first indicate a host
imminent predisposition with an altered tumor immune
surveillance probably mediated by a differential composi-
tion of host MICA-TM alleles in patients with colorectal
cancer.
At present, the there is no evidence that the MICA-TM
microsatellite polymorphism directly affects NKG2D inter-
action or shedding of MICA molecules. Interestingly, the
MICA-TM A4 and A9 alleles share methionine, M, at
amino acid position 129, whereas the A5 alleles always
code for valine, V, at this position (IMGT/HLA Database).
The MICA-TM alleles 5.1 and 6 do not form a haplogroup
with this polymorphic residue and can possess either M or
V at amino acid position 129. Steinle et al. [5] have shown
Tumor-related parameters Survival times (mean ± SD; months) (95% Confidence interval) p value
Tumor invasion
T1/2 (n=12) 81.8±11.4 (59.5–104.2) 0.209
T3/4 (n=42) 67.4±5.8 (54.5–80.3)
Lymph node involvement
N negative (n=28) 89.9±6.0 (78.1–101.7) 0.001
N positive (n=26) 48.6±7.9 (33.1–64.1)
UICC stages
UICC I/II (n=24) 96.7±4.9 (87.0–106.4) <0.001
UICC III/IV (n=30) 50.8±7.3 (36.4–65.23)
Distant metastasis
M0 (n=38) 86.7±5.4 (76.0–97.4) <0.001
M1 (n=16) 38.0±9.5 (19.4–65.7)
A4
No (n=42) 79.1±6.0 (67.2–91.0) 0.006
Yes (n=12) 46.4±12.1 (22.5–70.3)
A5
No (n=42) 65.3±6.6 (52.4–78.3) 0.042
Yes (n=12) 88.4±7.1 (74.3–102.5)
A5.1
No (n=16) 62.7±10.89 (41.4–84.1) 0.236
Yes (n=38) 73.3±6.3 (60.9–85.8)
A9
No (n=43) 75.7±6.0 (63.8–87.6) 0.034
Yes (n=11) 51.4±10.9 (30.0–72.8)
CA24
No (n=37) 64.8±6.6 (51.7–77.9) 0.156
Yes (n=11) 81.9±9.5 (63.2–100.6)
KRAS codon 12 mutations
No (n=39) 77.2±6.5 (64.4–90.0) 0.121
Yes (n=15) 54.5±10.5 (33.9–75.1)
Table V Survival of Patients
with Microsatellite Stable
Colorectal Cancer
Univariate analysis of tumor-
related survival times of patients
with microsatellite stable (MIN
negative) colorectal cancer and
selected MICA-TM (A4, A5,
A5,1, A9) and MICB C1_2_A
(CA24) alleles in association
with indicated clinicopathologi-
cal parameters (n=54). Kaplan–
Meier analysis and the log rank
test were used for comparisons
and statistical evaluation
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NKG2D, whereas M129 confers high NKG2D binding
affinity to NKG2D receptors involving the amino acid
position M129 might be responsible for the described
association with advanced tumor progression and reduced
tumor-related survival time. Thus, shedded MICA M129
might more powerfully impair NK and CD8 T-cell
responses in vivo and/or downregulate NKG2D expression
on effector cells. But, surface MICA M129 might also
directly control its pronounced downregulation upon
interaction with a strong-affinity MICA protein.
In other epithelial tumors, Lo et al. have described an
association of the MICA-TM A9 allele with gastric cancer
and a less schirrous phenotype [27]. The relevance of the
NKG2D-ligand immune response in gastric cancer is
further supported by Osaki et al. describing a decreased
NKG2D expression on CD8+ T cell in patients with gastric
cancer [28]. Busche et al. have shown a reduced staining of
MICA on the surface of lung cancer samples [29]. In
addition, the authors demonstrated in an experimental
human lung cancer therapy model that an upregulation of
MICA expression in lung cancer cells by adenoviral
transfection of expression plasmids was able to reestablish
the previously decreased NK cell-mediated antitumor
immunity. In thyroid carcinomas, MICA and MICB
expression was detected by immunohistochemistry on most
tumor samples and on thyroid cancer cell lines with a
correlation of their sensitivity to killing by NKG2D-
positive NK cells. Transient transfection of mutant BRAF
and KRAS oncogenes led to increased MICA and MICB
expression in thyroid cancer cells [30]. As shown in our
analysis, we only observed a trend for an association of the
MICB C1_2_A CA23 allele (p=0.087) with the detection
of KRAS mutations in colorectal cancer samples.
Differential expression of MICA molecules locally
present at the surface of tumor cells might additionally
regulate local tumor–immune interactions. We therefore
cannot rule out that alterations of MICA or MICB at the
level of transcription or protein synthesis might result in
different levels of MICA and MICB protein expression on
the surface of tumor cells. Therefore, the investigation of
MICA and MICB alleles at protein expression level on the
individual tumor samples will be of further interest. Several
studies using immunohistochemistry have shown a reduced
expression of MICA at the protein level on tumor cells [27,
29]. It is unclear whether the reduction in MICA protein
expression on tumor cells is caused by reduced MICA
synthesis or is the result of an increased shedding of MICA
molecules in cancer patients.
The factors involved in shedding of soluble MICA
molecules from tumor cells are only poorly understood. It is
assumed that metalloproteinases are involved in proteolytic
cleavage of soluble MICA molecules from the surface of
tumor cells, leading to inactivation of NKG2D mediated
antitumor response [31]. Elevated levels of soluble MICA
levels were described for patients with gastrointestinal
cancer [9]. Interestingly, the authors also report an
association of MICA levels with advanced staged of tumor
progression especially in patients with gastrointestinal
renal, prostate, and breast cancer with highest levels in
patients with metastatic disease. It is assumed that the
reduction of MICA expression by release and shedding
from the cell surface would potentially reduce the immu-
nogenetic signals of tumor cells becoming less detectable
for NK and T cells. These findings further support the
concept that the NKG2D/ligand system seems to play an
important role in the immune surveillance of tumor cells.
However, it remains to be determined if any of the
described MICA alleles might be related to differential
shedding of soluble MICA molecules and thereby influence
antitumor immunity and tumor progression.
Elevated antibodies against MICA were recently de-
scribed in tumor patients and in recipients of renal and heart
transplants with differential responses to immune therapy or
an increased rejection rate associated with a reduced graft
survival [32–34]. It is assumed that MICA antibodies are
able to opsonize cancer cells for presentation to dendritic
cells and induce tumor cell lysis through complement
fixation. In addition, genetic modifications of human Tcells
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Fig. 3 MICA-TM A4 or A9 haplotype in microsatellite stable
colorectal cancer patients. Kaplan–Meier analysis of tumor-related
survival times in association with MICA-TM A4 or A9 alleles in
patients with microsatellite stable colorectal cancer. Vertical lines
indicate censored observations for comparison of patients either
positive for MICA-TM A4 or A9 alleles (n=23) in comparison to
patients without MICA-TM A4 and A9 alleles (n=31, p≤0.001)
552 J Clin Immunol (2009) 29:545–554with chimeric NKG2D receptors might further increase
innate antitumor response [35].
In summary, these findings might indicate a host innate
immunogenetic antitumor surveillance associated with
advanced colorectal tumor progression and reduced tumor-
related survival based on the presence of specific MICA-
TM alleles involved in NKG2D-receptor activation.
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